Infor M3 strengthens Verla-Pharm Medicines GmbH from the inside
Case study

Infor M3 strengthens Verla-Pharm Medicines GmbH from the inside

2 min read Dec 08, 2016

Verla-Pharm Arzneimittel GmbH & Co.KG
Customer:
Verla-Pharm Arzneimittel GmbH & Co.KG
Verla-Pharm, the German market leader for magnesium drugs has been working with a completely modernised software landscape since the successful Go-live of the ERP project in October 2016. The central core is Infor M3 - one of the leading ERP solutions for pharmaceutical companies. The successful project implementation is the result of intensive and collaborative cooperation with the implementation partner BE-terna.

ERP system provides uniform company data

One of the main objectives of the implementation project was to connect the different software systems and to achieve a continuous mapping of the business processes. In addition to the industry-leading LIMS LabWare (Laboratory information system) and the MES PharmaSuite (Manufacturing Execution System), Verla-Pharm uses an automated high-bay storage system. Infor M3 is connected to all these systems via ESB (Enterprise Service Bus) and provides all information to the employees of Verla-Pharm where they are required.

Günther Hopf, Head of Development and Production

With Infor M3 we have modern and future-oriented ERP software. We see Infor M3 as the central hub of our software landscape, where we can attach pharma-specific modules of other suppliers.

About Verla-Pharm Arzneimittel

Verla-Pharm Arzneimittel has continued operations in Tutzing on the Starnberger See for over half a century as part of its 160 year pharmaceutical history. The steadily positive development of the brand item Magnesium Verla has a decisive influence on the company growth and the reputation of the Verla-Pharm in the market. The subsidiary Xenofit founded in 1988 and also located in Tutzing specialises in the production of sports nutrition and vitamin preparations.

Sector: Pharma
Headquarter: Tutzing (DE)
User: 100
Employees: 250

Like what you read?

Subscribe to our Newsletter and get relevant updates …